Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
CytoSorbents revenue
CytoSorbents's revenue is $35.6 million.
What is CytoSorbents's revenue?
- CytoSorbents's revenue growth from 2013 to 2024 is 1,369.23%.
- CytoSorbents has 160 employees, and the revenue per employee ratio is $222,465.
- CytoSorbents's peak quarterly revenue was $12.0M in 2020(q4).
- CytoSorbents peak revenue was $43.2M in 2021.
- CytoSorbents annual revenue for 2023 was 31.1M, -10.39% growth from 2022.
- CytoSorbents annual revenue for 2024 was 35.6M, 14.51% growth from 2023.
On this page
Zippi applies for you, and finds you a job.
CytoSorbents historical revenue
CytoSorbents's peak revenue was $43.2M in 2021. The peak quarterly revenue was $12.0M in 2020(q4).
CytoSorbents's revenue increased from $2.4m in 2013 to $35.6M currently. That's a 1,369.23% change in annual revenue.
CytoSorbents annual revenue
CytoSorbents annual revenue over time
| Fiscal year / year | CytoSorbents revenue |
|---|---|
| 2013 | $2.4M |
| 2014 | $4.1M |
| 2015 | $4.8M |
| 2016 | $9.5M |
| 2017 | $15.2M |
| 2018 | $22.5M |
| 2019 | $24.9M |
| 2020 | $41.0M |
| 2021 | $43.2M |
| 2022 | $34.7M |
| 2023 | $31.1M |
| 2024 | $35.6M |
Rate CytoSorbents' financial transparency
CytoSorbents annual growth
CytoSorbents saw the greatest revenue growth in 2014, when revenue increased by 170,077.12%.
CytoSorbents had the lowest revenue growth in 2018, when revenue changed by -99.85%.
CytoSorbents annual growth rate over time
| Year | CytoSorbents growth |
|---|---|
| 2014 | 70%↑ |
| 2015 | 16%↑ |
| 2016 | 99%↑ |
| 2017 | 59%↑ |
| 2018 | 49%↑ |
| 2019 | 11%↑ |
| 2020 | 64%↑ |
| 2021 | 5%↑ |
| 2022 | -20%↓ |
| 2023 | -10%↓ |
| 2024 | 15%↑ |
CytoSorbents quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
CytoSorbents quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2013 | $176,502 | $128,190 | $203,692 | $313,937 |
| 2014 | $569,572 | $667,280 | $1.0M | $873,651 |
| 2015 | $723,074 | $782,528 | $1.1M | $1.5M |
| 2016 | $1.6M | $1.9M | $2.1M | $2.6M |
| 2017 | $2.6M | $3.0M | $3.4M | $4.3M |
| 2018 | $4.4M | $5.2M | $5.1M | $5.5M |
| 2019 | $4.6M | $5.9M | $5.7M | $6.6M |
| 2020 | $8.2M | $9.8M | $10.5M | $12.0M |
| 2021 | $10.6M | $11.4M | $8.9M | $9.7M |
| 2022 | $7.9M | $7.3M | $6.5M | $7.7M |
| 2023 | $7.9M | $8.1M | $7.7M | $7.4M |
| 2024 | $9.0M | $8.8M | $8.6M | $6.5M |
CytoSorbents jobs nearby
Do you work at CytoSorbents?
Is CytoSorbents transparent about its revenue structure?
CytoSorbents financial information
| Company Type | Public |
| Employees Number | 160 |
| Date Founded | 1997 |
| Headquarters | Monmouth Junction, New Jersey |
| Number of Locations | 2 |
| Revenue | $35.6M |
| Net Income | -$32,812,583 |
| Gross Proft | $25.1M (2024) |
| PE Ratio | -8.18 |
| Tax Rate | 0.1% |
| Market Capitalization | $169.5M |
| Total Assets | $63,231,530 |
| Ticker | CTSO |
CytoSorbents jobs you might like
CytoSorbents financing
CytoSorbents received early financing of $1.1M on 2013-08-08.
| Series | Round size | Date |
|---|---|---|
| Post Ipo Debt | $1M | 08/2013 |
| Post Ipo Debt | $745K | 10/2013 |
| Post Ipo Debt | $10M | 07/2016 |
| Post Ipo Debt | $5M | 06/2017 |
| Grant | $719K | 08/2017 |
| Post Ipo Debt | $5M | 08/2019 |
CytoSorbents investors
| Investors | Security type |
|---|---|
| Bridge Bank | Post Ipo Debt |
| Bridge Bank | Post Ipo Debt |
| U.S. Army Medical Research & Development Command | Grant |
| Bridge Bank | Post Ipo Debt |
CytoSorbents competitors
CytoSorbents's top competitor, Incyte, earned an annual revenue of $4.2B.
CytoSorbents's smallest competitor is Invitro with revenue of $710.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Intersect ENT | $67,446 | $106.7M | 393 | - |
| Cantel Medical | $63,787 | $1.0B | 2,693 | - |
| Tandem Diabetes Care | $62,371 | $940.2M | 1,500 | 5 |
| CoolSculpting | $73,648 | $342.1M | 686 | - |
| ADVANCED NEUROMODULATION SYSTEMS INC | - | $100.1M | 750 | - |
| Psychemedics | $55,467 | $19.7M | 139 | - |
| Ldr | $61,132 | $164.5M | 562 | - |
| Incyte | $103,592 | $4.2B | 1,600 | 38 |
| Pernix Therapeutics Holdings | $77,393 | $146.1M | 171 | - |
| ExThera Medical | $44,871 | $5.0M | 38 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Most in demand jobs
Zippia gives an in-depth look into the details of CytoSorbents, including salaries, political affiliations, employee data, and more, in order to inform job seekers about CytoSorbents. The employee data is based on information from people who have self-reported their past or current employments at CytoSorbents. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by CytoSorbents. The data presented on this page does not represent the view of CytoSorbents and its employees or that of Zippia.
CytoSorbents may also be known as or be related to CYTOSORBENTS CORP, CytoSorbents, CytoSorbents Corp., CytoSorbents Corporation, Cytosorbents, Cytosorbents Corp, Cytosorbents Corporation, Cytosorbents Medical Inc. and Medasorb Technologies Corporation.